IP Library Granted Patent US 12,090,252
Granted Patent B2
US 12,090,252 · App. 16/647,441 · Granted Sep 17, 2024

Method for producing retinal tissues

Inventors: Daiki Nukaya (Tokyo, JP); Mototsugu Eiraku (Wako, JP); Yuiko Kinose (Wako, JP); Akishi Onishi (Wako, JP); Masayo Takahashi (Wako, JP); Yoshiki SASAI (Wako, JP)
Assignees: RIKEN; SUMITOMO PHARMA CO., LTD.
A61L27/3895A61L27/3891C12N5/062G01N33/5088A61L2430/16A61L2430/32C12N2501/155C12N2501/395C12N2501/999
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,090,252
App. No.
16/647,441
Granted
Sep 17, 2024
Kind
B2
Abstract

The present invention aims to provide a method for suppressing differentiation of ganglion cell, amacrine cell, horizontal cell and/or bipolar cell in a neural retina tissue containing photoreceptor precursor and/or photoreceptor, and the like. A method for suppressing differentiation of a ganglion cell, an amacrine cell, a horizontal cell and/or a bipolar cell in a neural retinal tissue containing a photoreceptor precursor and/or a photoreceptor, including a step of culturing a retinal tissue comprising a neural retinal progenitor cell and in any stage between a differentiation stage immediately after emergence of a ganglion cell and a differentiation stage where emergence rate of a cone photoreceptor precursor reaches maximum in a medium containing a thyroid gland hormone signal transduction pathway agonist.

Claims (43)

1. A method for suppressing differentiation of a ganglion cell, an amacrine cell, a horizontal cell and/or a bipolar cell in a neural retinal tissue with a layer comprising a photoreceptor precursor and/or a photoreceptor, comprising steps:

(1) differentiating pluripotent stem cells in a first medium into a retinal tissue comprising a neural retinal progenitor cell and in any stage between a differentiation stage immediately after emergence of a ganglion cell and a differentiation stage where emergence rate of a cone photoreceptor precursor reaches maximum, and

(2) suspension culturing the retinal tissue obtained in step (1) in a second medium containing a thyroid gland hormone signal transduction pathway agonist,

thereby obtaining the retinal tissue as an aggregate,

wherein a ratio of ganglion cells, amacrine cells, horizontal cells, and/or bipolar cells to other cells is less than the ratio in the retinal tissue obtained by steps (1) and (2) except for the absence of a thyroid gland hormone signal transduction pathway agonist in the second medium, and

wherein the first medium and/or the second medium in at least a part of step (2) is a medium containing a dorsalization signal transmitter selected from a group consisting of BMP signal transduction pathway agonist and SHH signal transduction pathway inhibitor at a concentration that suppresses expression of a ventral marker.

2. The method according to claim 1 , wherein the step (2) is performed up to a differentiation stage where a rod photoreceptor precursor and/or a bipolar cell emerge(s).

3. The method according to claim 1 , wherein the step (2) is performed up to a differentiation stage where an outer plexiform membrane is formed.

4. The method according to claim 1 , wherein the step (2) is performed up to a differentiation stage where a Muller cell emerges.

5. The method according to claim 1 , wherein the method suppresses formation of PAX6-negative/CHX10-strongly positive cell and PAX6-positive/CHX10-negative cell.

6. The method according to claim 1 , wherein the thyroid gland hormone signal transduction pathway agonist is triiodothyronine or thyroxine.

7. The method according to claim 6 , wherein the triiodothyronine has a concentration of 1-100 nM.

8. The method according to claim 1 , wherein the retinal tissue containing a neural retinal progenitor cell and in a differentiation stage immediately after emergence of a ganglion cell in the step (1) is a retinal tissue having a neural retinal progenitor cell content of not less than 50% based on the total number of cells.

9. A method for producing matured neural retinal tissue, or a neural retinal tissue that can be matured into a matured neural retinal tissue, comprising steps:

(1) differentiating pluripotent stem cells into a retinal tissue in an initial developmental stage, and

(2) culturing the retinal tissue obtained in step (1) in a first medium to obtain a retinal tissue containing a neural retinal progenitor cell and in any stage between a differentiation stage immediately after emergence of a ganglion cell and a differentiation stage where emergence rate of a cone photoreceptor precursor reaches maximum, and

(3) suspension culturing the retinal tissue obtained in step (2) in a second medium containing a thyroid gland hormone signal transduction pathway agonist,

thereby obtaining the retinal tissue as an aggregate,

wherein a ratio of ganglion cells, amacrine cells, horizontal cells, and/or bipolar cells to other cells is less than the ratio in the retinal tissue obtained by steps (1), (2), and (3) except for the absence of a thyroid gland hormone signal transduction pathway agonist in the second medium, and

wherein the first medium and/or the second medium in at least a part of step (3) is a medium containing a dorsalization signal transmitter selected from a group consisting of BMP signal transduction pathway agonist and SHH signal transduction pathway inhibitor at a concentration that suppresses expression of a ventral marker.

10. The production method according to claim 9 , wherein the second medium in step (3) comprises a dorsalization signal transmitter at a concentration that suppresses expression of a ventral marker.

11. The production method according to claim 9 , wherein the first medium in step (2) comprises a dorsalization signal transmitter at a concentration that suppresses expression of a ventral marker.

12. The production method according to claim 9 , wherein the matured neural retinal tissue has the following characteristics (i)-(iii):

(i) the proportion of the number of cells of the photoreceptor precursor and photoreceptor is not less than 40% based on the total number of cells;

(ii) a content of cone photoreceptor precursor and cone photoreceptor contained in photoreceptor precursor and photoreceptor is not less than 70%; and

(iii) a proportion of the number of cells of a bipolar cell, a ganglion cell, an amacrine cell and a horizontal cell is not more than 30% based on the total number of cells.

13. The production method according to claim 9 , wherein the neural retinal tissue that can be matured into a matured neural retinal tissue has the following characteristics (i)-(ii):

(i) the proportion of the number of cells of photoreceptor precursor and photoreceptor (CRX-positive cell) is not less than 11% based on the total number of cells; and

(ii) the proportion of the number of cells of CRX-positive and TRβ2-positive cells is not less than 7% based on the total number of cells; and

culturing is continued for 30-50 days, after recognition of emergence of the cone photoreceptor precursor.

14. The production method according to claim 9 , wherein the neural retinal tissue that can be matured into a matured neural retinal tissue has the following characteristics (i)-(ii):

(i) the proportion of the photoreceptor precursor and photoreceptor (CRX-positive cells) is not less than 25% based on the total number of cells; and

(ii) the photoreceptor precursor and/or photoreceptor (CRX-positive cell) are/is in contact with the apical surface, and at least two cells are present side by side along a straight line vertical to the tangent line of the apical surface; and

culturing is continued for 55-80 days after recognition of emergence of the cone photoreceptor precursor.

15. The production method according to claim 9 , wherein the step (3) includes the following steps (3-1) and (3-2):

(3-1) culturing the retinal tissue obtained in step (2) in a medium containing a thyroid gland hormone signal transduction pathway agonist up to day 30-80 after recognition of emergence of the cone photoreceptor precursor, and

(3-2) culturing the retinal tissue obtained in step (3-1) in a medium for 60-120 days in the presence of or in the absence of thyroid gland hormone signal transduction pathway agonist.

16. The production method according to claim 15 , wherein the medium used in step (3-2) is a medium containing a thyroid gland hormone signal transduction pathway agonist and/or a dorsalization signal transmitter at a concentration that suppresses expression of a ventral marker.

17. The production method according to claim 1 or 9 , wherein the dorsalization signal transmitter is BMP4.

18. The production method according to claim 17 , wherein the BMP4 has a concentration of 0.05-0.45 nM.

19. The production method according to claim 1 or 9 , wherein the dorsalization signal transmitter is Cyclopamine-KAAD.

20. The production method according to claim 19 , wherein the Cyclopamine-KAAD has a concentration of 0.01-100 μM.

21. The production method according to claim 15 , wherein the medium used in step (3-2) is a medium for maintaining a continuous epithelial structure.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2025
From: SUMITOMO PHARMA CO., LTD.
To: RACTHERA CO., LTD.
Reel/Frame 072825/0888 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 27, 2023
From: SUMITOMO CHEMICAL COMPANY, LIMITED
To: SUMITOMO PHARMA CO., LTD.
Reel/Frame 065666/0629 →
NAME AND ADDRESS CHANGE Recorded May 4, 2022
From: SUMITOMO DAINIPPON PHARMA CO., LTD.
To: SUMITOMO PHARMA CO., LTD.
Reel/Frame 059855/0333 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2022
From: DOR, AVNER; SHANY, YARON; DOUBCHAK, ARIEL; BERMAN, AMIT
To: SAMSUNG ELECTRONICS CO., LTD.
Reel/Frame 058586/0545 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 14, 2020
From: NUKAYA, DAIKI; EIRAKU, MOTOTSUGU; KINOSE, YUIKO; ONISHI, AKISHI; TAKAHASHI, MASAYO; SASAI, MIYUKI (LEGAL REPRESENTATIVE OF DECEASED INVENTOR YOSHIKI SASAI)
To: RIKEN; SUMITOMO DAINIPPON PHARMA CO., LTD.; SUMITOMO CHEMICAL COMPANY, LIMITED
Reel/Frame 052117/0928 →
Priority Claims (1)
JP 2017-177188 · Sep 14, 2017 · national
Continuity (1)
Related Publication 20210154370A1 · May 27, 2021